Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S. r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW COLLABORATION STRUCTURE ACHIEVES MEANINGFULLY IMPROVED FINANCIAL TERMS AND FLEXIBILITY FOR GALAPAGOS FOLLOWING THIS TRANSACTION, THE COMPANY WILL CONTINUE TO HAVE A MAJORITY OF ITS CASH REMAINING FOR ADDITIONAL STRATEGIC TRANSACTIONS AND OTHER CAPITAL ALLOCATION PRIORITIES OPPORTUNITY TO DEVELOP A POTENTIAL FIRST-IN-CLASS & BEST-IN-CLASS T CELL ENGAGER IN AUTOIMMUNE DISEASES WITH GAMGERTAMIG MANAGEMENT TO HOST CONFERENCE CALL TODAY, MARCH 31, 2026, AT 14:00 CET / 8:00 AM ET MECHELEN, BELGIUM; MARCH 31, 2026, 7.30 CET; REGULATED INFORMATION  ANNOUNCEMENT IN APPLICATION OF ARTICLE 7:97, 4/1 OF THE BCCA  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) (GALAPAGOS OR THE COMPANY) TODAY ANNOUNCED THAT IT HAS ENTERED INTO A BINDING AGREEMENT (THE "FRAMEWORK AGREEMENT") WITH GILEAD SCIENCES, INC. ("GILEAD") IN CONNECTION WITH GILEAD'S DEFINITIVE AGREEMENT TO ACQUIRE ALL OF THE OUTSTANDING EQUITY INTERESTS OF US-BASED OURO MEDICINES, LLC ("OURO"), A PRIVATELY HELD BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING T CELL ENGAGER THERAPIES FOR AUTOIMMUNE DISEASES. GAMGERTAMIG (OM336) IS A CLINICALSTAGE BCMAXCD3 T CELL ENGAGER DESIGNED TO ENABLE RAPID AND DEEP PLASMA AND BCELL DEPLETION FOLLOWING A SHORT DURATION, SUBCUTANEOUSLY ADMINISTERED TREATMENT COURSE.

GALAPAGOS AND GILEAD ENTER INTO BINDING AGREEMENT TO COLLABORATE ON ADVANCING FIRST IN CLASS T CELL ENGAGER PROGRAM FOR AUTOIMMUNE DISEASES

SUBJECT TO HIS ELECTION BY SHAREHOLDERS, THE BOARD INTENDS TO APPOINT MR. SANTINI AS CHAIR, SUCCEEDING JRME CONTAMINE

GALAPAGOS ANNOUNCES NOMINATION OF GINO SANTINI TO ITS BOARD OF DIRECTORS

MECHELEN, BELGIUM; MARCH 26, 2026, 21:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY PUBLISHED ITS ANNUAL REPORT FOR THE FINANCIAL YEAR 2025 AND ANNOUNCED THAT ITS ANNUAL SHAREHOLDERS' MEETING (AGM) AND AN EXTRAORDINARY SHAREHOLDERS' MEETING (EGM) WILL BE HELD SEQUENTIALLY ON TUESDAY, APRIL 28, 2026 AT 14:00 CET AND 15:00 CET AT SCHALINHOEVEDREEF 20T, 2800 MECHELEN, BELGIUM.

GALAPAGOS PUBLISHES 2025 ANNUAL REPORT AND ANNOUNCES ANNUAL AND EXTRAORDINARY SHAREHOLDERS' MEETINGS

GALAPAGOS INTENDS TO ENTER INTO A STRATEGIC COLLABORATION WITH GILEAD FOLLOWING GILEAD'S ACQUISITION OF OURO MEDICINES

GALAPAGOS AND GILEAD IN ADVANCED DISCUSSIONS TO COLLABORATE ON ADVANCING FIRST IN CLASS T CELL ENGAGER PROGRAM FOR AUTOIMMUNE DISEASES

MECHELEN, BELGIUM ; MARCH 117, 2026, 22:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) RECEIVED A TRANSPARENCY NOTIFICATION FROM BANK OF AMERICA.

GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATION FROM BANK OF AMERICA

MECHELEN, BELGIUM ; MARCH 10, 2026, 22:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) RECEIVED TRANSPARENCY NOTIFICATIONS FROM BANK OF AMERICA.

GALAPAGOS RECEIVES TRANSPARENCY NOTIFICATIONS FROM BANK OF AMERICA

MECHELEN, BELGIUM; MARCH 6, 2026, 22.01 CET;REGULATED INFORMATION  GALAPAGOSNV (EURONEXT & NASDAQ: GLPG)ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS CREATED 1,750,000 SUBSCRIPTION RIGHTSUNDERANEWSUBSCRIPTION RIGHTPLAN.

GALAPAGOS CREATES NEW SUBSCRIPTION RIGHT PLAN

SEASONED LIFE SCIENCES EXECUTIVE JOINS GALAPAGOS WITH STRONG TRACK RECORD IN CHANGE MANAGEMENT MECHELEN, BELGIUM; MARCH 5, 2026, 22:01 CET  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY ANNOUNCED THE APPOINTMENT OF TANIA PHILIPP AS CHIEF HUMAN RESOURCES OFFICER (CHRO), EFFECTIVE MARCH 4, 2026. MS. PHILIPP WILL ALSO JOIN THE MANAGEMENT COMMITTEE.

GALAPAGOS APPOINTS TANIA PHILIPP AS CHIEF HUMAN RESOURCES OFFICER

MECHELEN, BELGIUM ; MARCH 4, 2026, 22:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) RECEIVED TRANSPARENCY NOTIFICATIONS FROM BANK OF AMERICA.

MECHELEN, BELGIUM; FEBRUARY 23, 2026, 22:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FULL YEAR 2025 AND PROVIDED AN UPDATE ON THE FOURTH QUARTER 2025 AND ITS YEAR-TO-DATE PERFORMANCE.

GALAPAGOS REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES FOURTH QUARTER BUSINESS UPDATE

MECHELEN, BELGIUM ; FEBRUARY 16, 2026, 22:01 CET; REGULATED INFORMATION  GALAPAGOS NV (EURONEXT & NASDAQ: GLPG) RECEIVED A TRANSPARENCY NOTIFICATION FROM BANK OF AMERICA.

Galapagos NV

GLPG

Price

Financial Reports

No items found.

Press Releases

Galapagos NV

GLPG.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GLPG